With this regard, the approval of IDH1 inhibitors for patients with IDH1-mutated ND AML unsuitable for ICT and those with R/R disease allows a specifically tailored treatment [48,49,50,51,140,141,142,143]. This evidence concerns the gene IDH1 and acute myeloid leukemia.